Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid Enrollees in 2001

Journal of Clinical Psychiatry

Volumn 67, Issue 6, 2006, Pages 972-982

  Chen, Hua ^a   Reeves, Jaxk H ^b   Fincham, Jack E ^b   Kennedy, William K ^b   Dorfman, Jeffrey H ^c   Martin, Bradley C ^d  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUOXETINE; FOSPHENYTOIN SODIUM; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENYTOIN; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG LABELING; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 33745881360     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0615     Document Type: Article

References (30)

1. Blazinski C. Drugs Intended for the Treatment of Epilepsy and Schizophrenia are Often Used for Other Diseases. Decision Resources October 21; 2002. Summary available at: http://www.prnewswire.com/ cgi-bin/stories.pl? ACCT=104&STORY=/www/story/10-21-2002/ 0001823356&EDATE=. Accessibility verified May 4, 2006
2. Chawla H, Diwan N, Joshi K. Emerging trends in world pharmaceutical market: a review: Pharmatech Business Briefing 2004:22-24. Available at http://www.touchbriefings.com/pdf/890/PT04_3_chawla.pdf. Accessibility confirmed May 3, 2006
3. Barbui A, Ciuna A, Nose M, et al. Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatr Scand 2004;109:275-278
4. Chen H, Deshpande AD, Jiang R, et al. An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population. J Pharmacoepidemiol Drug Saf 2005;14:629-638
5. Fountoulakis K, Nimatoudis L, Lacovides A, et al. Off-label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004;3:4-14
6. Graves N. Anticonvulsants: choices and costs. Am J Manag Care 1998;4:S463-S467
7. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol 2003;56:569-575
8. Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004;329:75
9. Rosenheck R, Leslie D, Sernyak M. From clinical trial to real-world practice: use of atypical antipsychotic medication nationally in the department of veteran affairs. Med Care 2001;39:302-308
10. Stone K, Viera A, Parman C. Off-label application of SSRIs. Am Fam Physician 2003;68:498-504
11. Blumer J. Off-label uses of drugs in children. Pediatrics 1999;104:598-609
12. Conroy S, Choonara I, impicciatore P, et al. Survey of unlicensed and off-label drug use in pediatric wards in European countries. BMJ 2000;320:79-82
13. Nahata MC. Inadequate pharmacotherapeutic data for drugs used in children: what can be done? Paediatr Drugs 1999;1:245-249
14. Shelton R. The use of antidepressants in novel combination therapies. J Clin Psychiatry 2003;64:14-18
15. Thase M. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry 2002;63:95-103
16. Motsinger C, Perron G, Lacy T. Use of atypical antipsychotic drugs in patients with dementia. Am Fam Physician 2003;67:2335-2340
17. US Food and Drug Administration (FDA). FDA Issues Public Health Advisory for Antipsychotic Drugs Used for Treatment of Behavioral Disorders in Elderly Patients. FDA Talk Paper. Rockville, Md: US Food and Drug Administration; 2005. Available at http://www.fda.gov/bbs/ topics/ANSWERS/2005/ANS01350.html. Accessibility confirmed April 28, 2006.
18. Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 2004
19. Woodcock J. A Shift in the Regulatory Approach. Rockville, Md: US Food and Drug Administration; 1997. Available at http://www.fda.gov/ cder/present/diamontreal/mdex.htm. Accessibility confirmed April 21, 2006
20. MEDSTAT Group. Defining Mental Health and/or Substance Abuse (MH/SA) Claimants. Rockville, Md: Substance Abuse and Mental Health Services Administration; 2003. Available at: http:// www.mhsapayments.org/Defining_MH- SA_Claimants_2003-10.pdf. Accessibility verified April 21, 2006
21. US Food and Drug Administration (FDA). Guidance for Institutional Review Boards and Clinical Investigator Information Sheet: "Off-label" and investigational use of marketed drugs, biologics, and medical devices. 1998 Update:. FDA administration information sheet 1998. Rockville, Md: US Food and Drug Administration; 1998. Available at: http://www.fda.gov/oc/ohrt/irbs/ offlabel.html. Accessibility verified April 21, 2006
22. Romano CJ. Anticonvulsant therapy for dementia: shaking up current thinking. Neurol Rev 2001;9:60-64. Available at http:// www.neurologyreviews. com/oct01/nr_oct01_dementia.html. Accessibility verified April 28, 2006
23. Bains J, Birks J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database Syst Review 2002;4:CD003944
24. United States Public Health Service Office of the Surgeon General. Mental Health: Culture, Race, and Ethnicity: A Supplement to Mental Health: A Report of the Surgeon General. Rockville, Md: Department of Health and Human Services, U.S. Public Health Services; 2001. Available at: http://www.surgeongeneral.gov/ library/mentalhealth/cre/ execsummary-6.html. Accessibility verified May 16, 2006
25. Whitehead C, Moss S, Cardno A, et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002;2:CD002305
26. Hames A, Wynne HA. Unlicensed and off-label drug use in elderly people [letter]. Age Ageing 2001;30:530-531
27. Cohen L, Tessier E, Germain M, et al. Update on psychotropic medication use in renal disease. Psychosomatics 2004;45:34-48
28. Rost K, Smith R, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994;3:333-337
29. Fillit H, Geldmacher DS, Welter RT, et al. Optimizing coding and reimbursement to improve management of Alzheimer's disease and related dementias. J Am Geriatr Soc 2002;50:1871-1878
30. Greco A, Cascavilla L, Paris F, et al. Undercoding of Alzheimer's disease and related dementias in hospitalized elderly patients in Italy. Am J Alzheimers Dis Other Demen 2005;20:167-170